This New Medicare Pilot Program Offers GLP-1s For $50 A Month. Here’s What You Need To Know
Medicare has launched a new pilot program called Bridge that allows eligible beneficiaries to access GLP-1 obesity drugs from Novo Nordisk and Eli Lilly for $50 per month, a dramatic reduction from hundreds of dollars. However, the program faces implementation challenges and is only guaranteed through the end of 2027, creating uncertainty for patients starting long-term therapies.
Summary
Starting this week, millions of eligible Medicare patients gain access to GLP-1 obesity drugs through a new federal pilot program called Bridge, marking a significant shift in Medicare policy. Traditionally, Medicare has barred coverage of medications prescribed solely for obesity, but this program creates a temporary pathway for coverage. Eligible beneficiaries must meet certain requirements, including a BMI over 35 and the presence of certain obesity-related conditions, and can access these medications for a $50 monthly copay instead of the typical hundreds of dollars per month. This move could potentially reach as many as 20 million new patients according to Novo Nordisk and Eli Lilly's estimates, with officials expecting several million beneficiaries to enroll immediately. The program addresses a significant access gap for older Americans who have been unable to afford these popular weight loss drugs. However, the rollout faces practical challenges. Doctors must submit prior authorization requests to confirm patient eligibility before coverage is approved, and physicians are concerned that an influx of new patients could strain already busy clinics and pharmacies. More critically, the coverage is not permanent—unless the Trump administration extends or replaces the program, Bridge coverage is scheduled to expire by the end of 2027, and any permanent changes would require congressional approval. This creates a significant risk for patients who will begin long-term obesity therapies without knowing whether coverage will continue beyond 2027.
Key Insights
- GLP-1 obesity drugs have cost hundreds of dollars per month, making them out of reach for most older Americans on Medicare until this week's program launch
- The Bridge program represents a major shift because Medicare has traditionally barred coverage of medications prescribed solely for obesity
- Novo Nordisk and Eli Lilly estimate the program could reach as many as 20 million eligible patients, with several million expected to enroll immediately
- Physicians warn that a wave of new patients could put additional pressure on already busy clinics and pharmacies over the next couple of months
- The coverage through Bridge is scheduled to expire by the end of 2027 unless the Trump administration extends it, and permanent changes would require congressional approval
Topics
Transcript
[0:00] Popular weight loss drugs have remained out of reach for most older Americans in Medicare for years. That's because GLP-1s can cost hundreds of dollars per month, but that changes this week. Starting Wednesday, millions of eligible Medicare patients can access GLP-1 obesity drugs >> [music] >> from Novo Nordisk and Eli Lilly for a copay of just $50 per month. It's a major shift for a federal program that has traditionally barred coverage of medications prescribed solely for obesity. So, what happened? Well, there's a new Medicare pilot program called Bridge that's creating a temporary pathway for coverage. Patients [0:31] who meet [music] certain requirements, including those with a BMI of over 35 and people with certain obesity-related…
Full transcript available for MurmurCast members
Sign Up to AccessMore from CNBC
Why The U.S. Is Struggling To Keep Food Safe
The U.S. is experiencing the largest cyclospora outbreak in history, with over 10,000 cases reported. The inability to reliably trace contaminated food sources, exacerbated by federal funding cuts and the recent upheaval at the FDA, poses significant challenges for public health.
Who Makes The Elevators Americans Ride Every Day?
Otis, the world's largest elevator company, generates over $14 billion in annual revenue by servicing 2.5 million elevators globally, with over 90% of profits coming from maintenance and modernization rather than new installations. Despite strong long-term growth prospects driven by urbanization and infrastructure modernization, Otis has recently faced stock price headwinds due to service margin declines and China's weakened construction market.
Why Crypto Is Betting Big On AI Agents
The crypto industry is pivoting from targeting human users to focusing on AI agents as its next growth engine, with major companies like Circle, Kraken, and Coinbase building infrastructure for agents to autonomously manage wallets, execute trades, and make payments. Stablecoins and blockchain's always-on nature make crypto technically well-suited for machine-to-machine transactions that traditional banking cannot support, potentially creating a new stream of payment activity beyond speculation.
Who dominates hybrid car sales?
Hybrid vehicles are experiencing explosive growth in the US market, reaching a record 15.4% share in 2026. Toyota dominates the segment with over twice the sales of competitors, though Hyundai Motor Group has surpassed Honda to claim the number two position.
How SpaceX's AI ambitions took over Memphis
Elon Musk's XAI (now SpaceX AI) has rapidly built massive AI data centers in Memphis, Tennessee, including Colossus 1 completed in just 123 days. The expansion has sparked significant backlash from residents and environmental advocates over noise pollution, air quality concerns, and the operation of dozens of gas turbines without proper permits at a power plant in South Haven, Mississippi.